A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT07783802

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07783802
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Japan, Puerto Rico (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07783802. Randomized; double masking; primary purpose treatment. Start 2026-08-27 (actual); primary completion 2027-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Acronym
CLARITY-CRP
Condition
Atherosclerosis
Condition
Cardiovascular Disease
Condition
Obesity
Condition
Hypertension
Condition
Diabetes Mellitus, Type 2
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Clazakizumab
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07783802
Content hash
57f8eaa224e72767b4f0a3c2bd10277df7ef06451065bc7848884195ff6eeca3